



(86) Date de dépôt PCT/PCT Filing Date: 2008/03/14

(87) Date publication PCT/PCT Publication Date: 2008/09/18

(45) Date de délivrance/Issue Date: 2015/07/21

(85) Entrée phase nationale/National Entry: 2009/09/15

(86) N° demande PCT/PCT Application No.: AU 2008/000358

(87) N° publication PCT/PCT Publication No.: 2008/109956

(30) Priorité/Priority: 2007/03/15 (AU2007901326)

(51) Cl.Int./Int.Cl. *A61K 39/102* (2006.01),
A61P 11/00 (2006.01), *A61P 11/06* (2006.01)


(72) Inventeurs/Inventors:
DUNKLEY, MARGARET, AU;
CLANCY, ROBERT, AU;
CRIPPS, ALLAN WILLIAM, AU;
OTCZYK, DIANA CHRISTINE, AU

(73) Propriétaire/Owner:
HUNTER IMMUNOLOGY LIMITED, AU

(74) Agent: BLAKE, CASSELS & GRAYDON LLP

(54) Titre : TRAITEMENT OU PROPHYLAXIE DE L'ASTHME

(54) Title: TREATMENT OR PROPHYLAXIS OF ASTHMA



(57) **Abrégé/Abstract:**

There is provided a method for prophylaxis or treatment of asthma in an individual. The method comprises administering to the individual an effective amount of a Non-typable Haemophilus influenzae (NTHi) vaccine. One or more embodiments are particularly suitable for prophylaxis or treatment of intrinsic asthma. The vaccine is typically an oral whole killed NTHi vaccine.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 September 2008 (18.09.2008)

PCT

(10) International Publication Number
WO 2008/109956 A1

(51) International Patent Classification:

A61K 39/102 (2006.01) A61P 11/06 (2006.01)
A61P 11/00 (2006.01)

OTCZYK, Diana Christine [AU/AU]; 33 Geraldton Drive, Robina, Queensland 4226 (AU).

(21) International Application Number:

PCT/AU2008/000358

(74) Agents: ADAMS PLUCK et al.; Suite 3, Level 1, 20 George Street, Hornsby, New South Wales 2077 (AU).

(22) International Filing Date: 14 March 2008 (14.03.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

2007901326 15 March 2007 (15.03.2007) AU

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(71) Applicant (for all designated States except US): HUNTER IMMUNOLOGY LIMITED [AU/AU]; Suite 209, 18 Rodborough Road Frenchs Forest, Sydney, New South Wales 2086 (AU).

(72) Inventors; and

(75) Inventors/Applicants (for US only): DUNKLEY, Margaret [AU/AU]; 80 Dangerfield Drive, Elmore Vale, New South Wales 2287 (AU). CLANCY, Robert [AU/AU]; 4 Neutral Street, North Sydney, New South Wales 2060 (AU). CRIPPS, Allan William [AU/AU]; 33 Geraldton Drive, Robina, Queensland 4226 (AU).


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(54) Title: TREATMENT OR PROPHYLAXIS OF ASTHMA

FIGURE 3



(57) Abstract: There is provided a method for prophylaxis or treatment of asthma in an individual. The method comprises administering to the individual an effective amount of a Non-typable Haemophilus influenzae (NTHi) vaccine. One or more embodiments are particularly suitable for prophylaxis or treatment of intrinsic asthma. The vaccine is typically an oral whole killed NTHi vaccine.

WO 2008/109956 A1

1.

TREATMENT OR PROPHYLAXIS OF ASTHMA

5 FIELD OF THE INVENTION

The invention relates to the administration of a bacterial vaccine for the prophylaxis or treatment of asthma.

10 BACKGROUND OF THE INVENTION

Asthma is a chronic inflammatory condition of the airways characterised by reversible airway obstruction, and has traditionally been classified as extrinsic (due to allergic reaction to inhaled allergens such as pollens and house dust mite) or intrinsic
15 (not due to classical allergy), the mechanism for which is unknown. This latter form of asthma has been called “idiopathic” asthma

In a recently reported study based on diagnosed asthma subjects, asthma was classified based on differences in eosinophil and neutrophil counts in sputum (Simpson et al, 2006). The subjects in the study were divided into different asthma subtypes
20 based on the presence of these cell types compared to healthy control subjects. Several asthma sub-types were identified including neutrophilic asthma (> 61% neutrophils) and eosinophilic asthma (>1.01% eosinophils). The neutrophilic asthma group comprised approximately 20% of the overall number of asthmatics. The study further reported persistent neutrophilia in the majority of these subjects over both short term (4
25 week) and long term (mean 5.3 years) intervals between sampling despite no subject reporting respiratory tract infection during the month prior to assessment. While subjects with asthma were found to have higher levels of intracellular bacteria and macrophages than healthy controls, no significant differences were found between neutrophilic asthmatics and the other asthma groups. Indeed, the levels of bacteria
30 found were stated to be less than that consistent with acute bacterial infections, and the report concluded there was no evidence of bacterial infection to explain the inflammatory process of neutrophilic asthma.

2.

Non-typable *Haemophilus influenzae* (NTHi) is the most common pathogenic bacteria associated with chronic bronchitis (CB) (Sethi, 2001). NTHi can be found in the upper airways (eg., nose, middle ear, throat and sinuses) of healthy individuals and patients with CB (Sethi, 2001) as well as several locations of the respiratory tract, including the lumen, adhering to mucosal epithelial cells in the interstitium of the submucosa (Moller, 1998). Studies of non-obstructive and obstructive CB have observed that a large proportion of patients have persistent infection with NTHi (Murphy, 2004).

Both NTHi and *Staphylococcus aureus* have previously been shown to induce non-IgE-mediated and enhanced IgE-mediated histamine release from mast cells obtained by bronchoalveolar lavage from the airways of patients with CB. In the case of NTHi, it has been reported that exotoxin may be responsible for the enhancement of IgE-mediated histamine release (Clements, 1990). Immune cells isolated from patients with CB during acute exacerbations have been shown to be both sensitized and hyperactive to the patient's own bacteria (Norn, 1994). Several studies have also reported specific IgE antibodies produced in response to respiratory infection by fungi (eg., *Aspergillus*) and viruses (eg., respiratory syncytial virus, parainfluenza virus, [Welliver, 1982]) and bacteria, (*S. pneumoniae* [Kjaergard, 1996; Tee, 1982; Pauwels, 1980], *S. aureus* [Rhode, 2004; Tee, 1982], *Pseudomonas aeruginosa* [Shen, 1981], and *Mycoplasma pneumoniae* [Seggev, 1996]). IgE antibodies specific for NTHi have also been identified in the serum of patients with CB (Kjaergard, 1996; Tee 1982) and cystic fibrosis (Tee, 1982).

In a study of patients with bronchial asthma, IgE antibodies to NTHi were found in 29%. Antibodies to NTHi and/or *Streptococcus pneumoniae* were also present in 22% of patients with no other IgE mediated hypersensitivity. However, higher levels of IgE bacterial antibodies were found in patients with demonstrable IgE antibodies to various inhalant antigens (suggesting an allergic phenotype) (Pauwels, 1980). While it has been hypothesised that bacterial infections may play a role in the induction and exacerbation of asthma, it has been considered that exacerbation of asthma is predominantly triggered by viral infection. Indeed, the clinical effect of bacterial vaccines in the treatment of asthma has been questioned leading to international (WHO) recommendations that bacterial vaccines have no role in modern asthma treatment.

3.

Despite massive amounts of research focused on therapeutic asthma intervention and treatment, the condition remains a major, costly and growing problem in modern Westernised societies.

5 SUMMARY OF THE INVENTION

Broadly stated, the invention stems from the recognition by the inventors that Non-typable *Haemophilus influenzae* (NTHi) can act as a trigger for severe asthma as a result of persistent colonisation and/or recurrent exposure to NTHi. In particular, the present inventors have found that IgE antibody to NTHi is a highly significant mediator of asthma (often in a complex multi-factorial situation). Without being limited by theory, it is believed by the inventors the reduction of inhaled/colonising NTHi in the lower airways reduces or essentially avoids the activation of mechanisms that trigger asthma. By reducing the induction of asthma, therapy with NTHi vaccine as described herein may also reduce asthma treatment needs and associated asthma medication.

Hence, in an aspect of the invention there is provided a method for prophylaxis or treatment of asthma in an individual, comprising administering to the individual an effective amount of an NTHi vaccine.

The vaccine can be any NTHi vaccine which induces an effective immune response against the bacteria. Typically, the vaccine will be an oral vaccine against NTHi and more usually, an oral killed NTHi vaccine.

In another aspect of the invention there is provided an oral vaccine for prophylaxis or treatment of asthma, the vaccine comprising at least one antigen of NTHi together with a physiologically acceptable carrier.

In another aspect of the invention there is provided the use of at least one antigen for generating an immune response against NTHi for prophylaxis or treatment of asthma in an individual.

The antigen can, for instance, be an antigen selected from the group consisting of killed or inactivated NTHi isolates, NTHi fractions and antigenic outer membrane components (eg., surface antigens or fragments thereof) of NTHi.

Typically, whole killed NTHi will be used in a vaccine or method for prophylaxis or treatment of asthma as described herein.

4.

The individual can have diagnosed asthma or be an individual whom is deemed at risk of asthma such as a current or ex-smoker, an individual with recurrent airway infections, chronic cough and sputum (eg., as in chronic bronchitis), and/or intrinsic asthma. In at least one form, the individual will have one or more parameters indicative of exposure to NTHi such as an elevated neutrophil level, the presence of NTHi in sputum or saliva, and/or antibodies specific for NTHi. At least some embodiments of the invention have particular application in the prophylaxis or treatment of neutrophilic asthma.

Advantageously, administration of an NTHi vaccine in accordance with one or more embodiments of the invention can lead to a reduction in IgE antibodies and/or a reduction in the symptoms or severity of the asthma (eg., intrinsic or neutrophilic asthma) in the individual.

Throughout this specification the word “comprise”, or variations such as “comprises” or “comprising”, will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

Any discussion of documents, acts, materials, devices, articles or the like that has been included in this specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed anywhere before the priority date of this application.

The features and advantages of the invention will become further apparent from the following detailed description of embodiments thereof.

BRIEF DESCRIPTION OF THE ACCOMPANYING DRAWINGS

Figure 1 is a graph showing mean number of NTHi isolated in gargle of a placebo study group;

Figure 2 is a graph showing serum NTHi-specific IgG levels in the placebo group and a treatment group immunized with an oral killed NTHi vaccine; and

5.

Figure 3 is a graph showing saliva NTHI-specific IgG levels in the placebo group and the treatment group immunized with an oral killed NTHi vaccine.


DETAILED DESCRIPTION OF EMBODIMENTS OF THE INVENTION

5

Asthma is defined clinically by wheeze, reversible airways obstruction and bronchial hyperactivity. The commonest cause of asthma is IgE mediated hypersensitivity to inhaled allergens resulting in the classification of asthma as “extrinsic” or “intrinsic”. However, individuals with longstanding asthma can develop cough and sputum stemming from lung damage and associated recurring infection of the airways. There are also, for example, bronchitic individuals with longstanding cough and sputum who develop wheeze, and individuals with recurrent asthma and airways infection.

Conventionally in asthma studies care has been taken to study discrete groups and generally, subjects with clearly defined asthma (eg., classical extrinsic asthma) are separated from other groups (eg., those with smoking-related airways disease) leading to the studies being conducted on defined groups of asthmatics in isolation of other groups of asthmatics. However, this is an artificial categorization and rather, it is more realistic to view asthma as a spectrum of airways disease as illustrated in Scheme 1.

20



Scheme 1: Spectrum of asthma disease

25

Various Different observations have been made with respect to these different clinical manifestations of asthma. In brief, these can be summarised as follows.

- The induction of IgE antibody to inhaled antigens (eg., pollens) gives rise to classical allergic asthma in which allergen-specific IgE binds to mast

6.

cells causing degranulation of the mast cells and releasing of mediators such as histamine that give rise to allergic symptoms.

- Colonisation of damaged airways and intermittent viral infection can lead to neutrophil flux into the bronchus (acute bronchitis) (usually associated with wheeze – thought to follow “inflammation” of the bronchus).
- Smoking leading to lung damage can render the subject prone to infection of the airways.

However, many asthma subjects with clinically diagnosed asthma are ‘mixed’ with respect to these components and it is proposed that this spectrum of asthma disease can be reconciled by recognition that different pathogenic pathways can lead to asthma and that these pathways can co-exist. In particular, without being limited to theory, it is thought by the inventors that the dominant cause of wheeze in many asthmatics without demonstrable classical allergen hypersensitivity (eg., negative tests for IgE antibody to house dust, pollens and the like, and/or whom have elevated eosinophil counts) is due to an IgE antibody mediated reaction to colonising and/or recurrent exposure NTHi in conjunction with the ability of NTHi to induce and activate neutrophils. Specifically, NTHi vaccine can reduce the load of NTHi to the small airways, and provide effective treatment for so-called “intrinsic asthma”.

More broadly, benefit from NTHi vaccine can be derived by those individuals exhibiting one or more parameters indicative of exposure to NTHi such as elevated neutrophil levels (with or without elevated eosinophil levels), current NTHi infection as for instance indicated by NTHi in sputum or saliva and/or NTHi specific antibody, and those individuals with damaged airways such as arising from smoking (chronic pulmonary obstructive disease (COPD)) or chronic bronchitis (particularly those individuals with wheeze). It is recognised, for instance, that individuals with damaged airways are highly prone to infection/colonisation by NTHi and other bacterial pathogens. While damage to airways classically follows smoking, extrinsic asthma can also damage the airways (hence, later onset of cough and sputum associated with NTHi infection). Benefit may also occur in asthmatic individuals with combined mechanisms (eg., atopic subjects with IgE antibody to NTHi), and the treatment of asthma and asthma symptoms in general as a result of decrease or avoidance of induction of IgE production resulting from exposure to NTHi.

7.

Antibody levels can be measured in blood, serum, plasma, sputum or saliva samples using any suitable conventionally known assay protocol including enzyme linked immunosorbent assay (ELISA) or other immunoassay. NTHi-specific antibody can be selected from one or more of IgA, IgM, IgG and IgE and subclasses thereof, such as IgG1 and/or IgG3. Total IgE and/or NTHi specific IgE antibody will generally be measured in sputum or saliva sample. Neutrophil levels can also be measured in saliva or sputum using any appropriate conventionally known assay including microscopic evaluation following cell staining. Similarly, any suitable method known in the art can be employed to determine NTHi counts/level of NTHi infection. Antibody levels, neutrophil levels and NTHi counts can be compared against corresponding reference level(s) derived from classical extrinsic asthmatics (eg., exhibiting eosinophilic and/or hyper-responsiveness) or for example, a non-asthmatic control or other suitable reference group. Statistical methods for differentiating asthma groups are for instance, described in Simpson et al, 2006.

The vaccine utilised in a method of the invention will typically contain whole killed or inactivated (eg., attenuated) NTHi isolate(s) (eg., formalin-killed). However, soluble or particulate NTHi antigen comprising or consisting of outer cell membrane and/or surface antigens can be utilised as well, or instead of, whole killed organisms. In one or more embodiments, the outer cellular membrane fraction or membrane protein(s) of the selected NTHi isolate(s) will be utilised. For instance, NTHi OMP P6 is a highly conserved 16-kDa lipoprotein (Nelson, 1988) which is a target of human bactericidal antibody and induces protection both in humans and in animal models. In chronic pulmonary obstructive disease (CPOD), OMP P6 has been shown to evoke a lymphocyte proliferative response that is associated with relative protection from NTHi infection (Abe, 2002). Accordingly, OMP P6 or any other suitable outer membrane NTHi proteins, polypeptides (eg., P2, P4 and P26) or antigenic fragments of such proteins or polypeptides can find application in the NTHi vaccine.

Soluble and/or particulate antigen can be prepared by disrupting killed or viable selected NTHi isolate(s). A fraction for use in the vaccine can then be prepared by centrifugation, filtration and/or other appropriate techniques known in the art. Any method which achieves the required level of cellular disruption can be employed including sonication or dissolution utilising appropriate surfactants and agitation, and

8.

combination of such techniques. When sonication is employed, the isolate can be subjected to a number of sonication steps in order to obtain the required degree of cellular disruption or generation of soluble and/or particulate matter of a specific size or size range.

- 5 The non-typable *H. influenzae* isolate HI-164 (Hunter Immunology Limited, Frenchs Forest, NSW 2086, Australia) is particularly suitable for use in vaccines for the prophylaxis or treatment of asthma as described herein.

The vaccine will typically comprise the selected bacterial isolate(s) and/or antigens in an amount of from about 0.1% to 100% w/w of the vaccine composition.

- 10 An effective dosage of the vaccine will take into account the proposed mode of delivery and nature of the vaccine (eg. powder, liquid, aerosol delivery etc). For whole killed vaccines, the dosage of the, or each, bacterial isolate administered will typically be in a range of about 10^9 to about 10^{12} killed bacteria, and more preferably from about 10^{10} to about 10^{11} killed bacteria. The optimum dosage of the vaccine can be determined by
- 15 administering different dosages to different groups of test mammals, prior to subsequently infecting the animals in each group with NTHi, and determining the dosage level required to achieve satisfactory clearance of the pathogen.

- The vaccine can be administered in accordance with any regimen suitable for generating an effective immune response against NTHi infection. For example, a single
- 20 dose of the vaccine can be administered once per year pre-winter. One or more “booster” doses of the vaccine administered at an interval of a number of weeks or months may also be given. Alternatively, a number of doses of the vaccine maybe administered over the course of a number of weeks in order to generate an effective immune response against infection and/or colonisation by NTHi.

- 25 The vaccine itself can be a freeze-dried or lyophilised vaccine reconstituted utilising a physiologically acceptable buffer or fluid. The vaccine can also contain one or more anti-caking agents, preservatives such as thimerosal or which are otherwise suitable for the proposed mode of administration, stabilisers such as amino acids and sugar moieties, sweetening agents such sucrose, lactose or saccharin, surfactants, pH
- 30 buffering agents and pH modifiers such sodium hydroxide, hydrochloric acid, monosodium phosphate and/or disodium phosphate, a pharmaceutically acceptable carrier such as physiologically saline, solvents and dispersion media and isotonic

9.

preparations. The vaccine can also comprise one or more adjuvants. Suitable adjuvants include for instance cholera toxin B subunits and conventionally known alum adjuvants. Typically, although not exclusively, the vaccine is non-adjuvanted.

Use of such ingredients and media in vaccines is well known in the art. Except
5 insofar as any conventional media or agent is incompatible with the NTHi isolate(s) or antigens, or the proposed mode of administration, their use the vaccines that can be employed in methods embodied by the invention is specifically encompassed. Supplementary active agents for boosting the immune response including for instance, probiotic microorganisms, fractions and biological products thereof, and appropriate
10 cytokines, can also be included to the vaccine. Pharmaceutically acceptable carriers and combinations of ingredients useful in vaccine compositions of the present invention may for instance be found in handbooks and texts well known to the skilled addressee such as "Remington" The Science and Practice of Pharmacy (Mack Publishing Co., 1995)".
15 Specific examples of adjuvants include cholera toxin B subunit and conventionally known alum adjuvants.

The oral killed bacterial vaccine can be administered as a dry powder or in liquid form. Administration can for example be achieved by injection (eg. subcutaneous, or intravenous), orally such as by dosage unit form (eg tablet, capsule or
20 dosed liquid form) instillation, or as a spray.

Particularly suitable forms of NTHi vaccine that can be administered in accordance with one or more embodiments of the invention include enterically coated tablets, capsules and dragees.

The individual to whom the vaccine is administered in accordance with the
25 invention will normally be a human being although the vaccine may also be administered to any suitable mammalian asthma model. The invention is further described below by way of a non-limiting Examples.

10.

EXAMPLE 1 Subjects with chronic airways disease have high levels of IgE antibody to NTHi

A study was performed in which subjects with chronic obstructive pulmonary disease (COPD) and an age-matched control group were assessed for levels of total IgE and NTHi-specific IgE in saliva, serum and sputum. A physical examination and a comprehensive questionnaire which included data on sex, age, smoking habits, and respiratory symptoms were completed. Use of corticosteroids and antibiotics were recorded from all subjects. Lung function was assessed by spirometry. None of the healthy controls were active smokers or had a history of ever having smoked. All but one of the subjects in the COPD group exhibited wheeze. Wheeze was defined as a wheezing or whistling sound in the chest at any time. None of the subjects studied had a respiratory infection within the preceding month. All patients were clinically stable. Saliva and bloods samples were collected.

15

1.1 Methodology**1.1.1 Saliva**

Whole paraffin stimulated saliva was collected for 10 mins in ice-chilled tubes by mild suction, clarified by centrifugation at 20,000 x g for 20 mins at 4°C and the clear supernatant was kept frozen at -70°C until analysed.

20

1.1.2 Serum

Ten millilitres of blood was collected by routine venipuncture and allowed to clot at room temperature, centrifuged at 5,000 x g at 4°C for 10 mins, and serum stored at -70°C until analysed.

25

1.1.3 Sputum sol.

In general, subjects were instructed to expectorate on arising and to keep samples refrigerated. Sputum samples were assessed for oropharyngeal contamination by microscopic examination according to the criteria described by Courcol et al (1985). Sputum sol was prepared from acceptable samples by centrifugation at 4°C for 60 mins at 30,000 x g and stored at -70°C until analysed.

30

11.

1.1.4 Preparation of NTHi antigens

A zwittergent extract of NTHi OMP was prepared as described by Murphy et al (1988). P6, a highly conserved 16-kDa lipoprotein of NTHi, was purified using preparative polyacrylamide gel electrophoresis (PAGE) by the sodium dodecyl sulphate (SDS) method as described by Kyd et al (1994). Preparative SDS-PAGE for purification of P6 was performed using a Bio-Rad 491 Cell (BioRad, Hercules, CA). SDS-PAGE was carried out using the PHAST System (Pharmacia Piscataway, NJ) to analyse the OMP zwittergent and P6 fractions with 10-15% gradient gels. Low molecular weight standards (Pharmacia) were run on each gel. Gels were stained with coomassie blue and silver nitrate.

1.1.5 IgE Enzyme linked immunosorbant assay (ELISA)

Goat anti-human IgE (Tago, Inc. CA) at a concentration of 2.0 µg/ml was used for the measurement of total IgE in samples. IgE antibodies were measured by ELISA. Briefly, flat-bottomed 96-well ELISA plates (Immunoplate I; Polysorp, Nunc, Roskilde, Denmark) were coated overnight at 4°C with 100 µl of antigen at the appropriate concentration in sodium-bicarbonate buffer (pH 9.6) or sodium-bicarbonate buffer alone. The wells were washed three times with PBS pH 7.2 containing 0.05% (v/v) Tween 20 (PBS/Tween) and then 100 µl of 1% (w/v) BSA (Radioimmunoassay grade; Sigma, St Louis, MO) in PBS/T was added and left for 60 min at 37°C. The wells were washed with PBS/T and then 100 µl of sample diluted in 1% BSA/PBS/T were added to each well. The plates were incubated for an additional 60 min at 37°C, after which they were washed and 100 µl of biotinylated goat anti-human IgE (Tago, Inc. California, USA) diluted 1:1000 in 1% BSA/PBS/T was added and incubated for another 60 min at 37°C. After washing, 100 µl of peroxidase-conjugated streptavidin (Tago) diluted 1:40,000 in 1% BSA/PBS/T was added to each well and incubated for 45 min at 37°C. After washing, 100 µl of enzyme substrate 3,3',5,5'-tetramethyl-benzidine (Sigma) in substrate buffer was added to each well and incubated for 15 - 30 min at room temperature. The reaction was stopped with 100 µl of sulphuric acid (1.0 M) and absorbance was read at 490 nm on an ELISA plate reader. Standard curves were generated by running five two fold dilutions of goat anti-human IgE (2.0 µg/ml)

12.

(Bioclone, Australia) for the measurement of total IgE in samples and pooled serum from 10 chronic bronchitic subjects for the measurement of OMP IgE and P6 IgE in samples. Standard curves and samples were tested in duplicate. The absorbance of samples in carbonate buffer wells was subtracted from each antibody coated well to give the final result. The sensitivity range for total IgE was 0.15 - 2.43 ng/ml. Checkerboard titrations were conducted to optimize all antibody concentrations and useful ranges for protein standard concentrations and sample dilutions.

1.2 Serum and sputum IgE levels in control and treatment groups

Total IgE and NTHi IgE antibodies were measured by ELISA assay as described in Example 1.1.5. The patient profile is shown in Table 1a. The values obtained are shown in Table 1b (values presented represent the mean +/- SEM).

Table 1a: Subject profile

	Controls (9)	Chronic obstructive airways disease with asthma (11)
Age (yrs)	33 (23-42)	46 (23-61)
Smokers (%)		
Current	0	64
Ex-smokers	0	10
FEV1 (L)	-	2.6 (1.2-4.7)

13.

Table 1b: Total IgE, IgE to NTHi OMP, and IgE to NTHi P6 in subjects with recurrent airways infection and asthma

	Controls		Chronic obstructive airways disease with asthma		
	Saliva	Serum	Saliva	Serum	Sputum
Total IgE (ng/ml)					
Mean \pm SE	5.4 \pm 0.7	401 \pm 92	5.0 \pm 0.4	438 \pm 100	11.5 \pm 1.6
Median	5.4	290	4.8	297	11.4
Range	1.6 – 9.3	210 – 1,093	2.4 – 7.0	131 – 1,172	4.1 – 21.3
OMP IgE (EU/ml)					
Mean \pm SE	ND.	14 \pm 4	0.26 \pm 0.05	79 \pm 14	0.34 \pm 0.9
Median		12	0.19	80	0.25
Range		2 - 35	0.11 – 0.66	11 - 176	0.11 – 1.16
P6 IgE (EU/ml)					
Mean \pm SE	ND.	10 \pm 5	ND.	61 \pm 15	0.33 \pm 0.6
Median		7		36	0.25
Range		2 – 30		13 - 158	0.21 – 0.67

5 ND = Not detectable
EU = Elisa Units

1.3 IgE levels and allergic airways disease

10 The relationship between IgE level and allergic respiratory disease in subjects was evaluated. The patient profile is shown in Table 2a. In brief, subjects with recurrent acute bronchitis with bronchospasm (most of whom smoke and have early chronic airways disease) were found to have high levels of IgE antibody irrespective of

14.

existence of allergic disease. Total IgE and NTHi specific IgE levels are shown in Table 2b (values presented represent the mean +/- SEM).

Table 2a: Subject profile

5

	Controls (9)	Chronic obstructive airways disease with asthma (17)
Smokers (%) (or ex-smokers)	0%	100%
FEV1 (L)	1.95 (1.35-2.55)	0.5 (0.2-1.14)

Table 2b: Total IgE and IgE specific to NTHi antigens (OMP & P6)

	Controls		COPD		
	Saliva	Serum	Saliva	Serum	Sputum
Total IgE (ng/ml)					
Mean ± SE	4.0 ± 1.0	490 ± 118	8.5 ± 1.2	992 ± 224	11.8 ± 1.7
Median	2.8	401	8.4	784	9.6
Range	1.1 – 9.4	119 – 1,199	2.2 – 20.6	112 – 3,822	1.9 – 22.7
OMP IgE (EU/ml)					
Mean ± SE	0.15 ± 0.03	15 ± 3	0.26 ± 0.04	257 ± 54	0.17 ± 0.04
Median	0.13	15	0.16	202	0.15
Range	0.08 – 0.27	5 - 32	0.11 – 0.56	33 - 801	0.09 – 0.40
P6 IgE (EU/ml)					
Mean ± SE	ND.	86 ± 36	ND.	182 ± 43	ND.
Median		55		122	
Range		6 - 361		3 - 523	

15.

1.4 Discussion

The results presented in Examples 1.2 and 1.3 show no significant difference in the level of total IgE in control and COPD groups in serum and saliva. However, a significant increase in IgE OMP antibody in the COPD group compared to control group (P<0.01) was found, and both IgE OMP antibody and IgE P6 antibody were detected in sputum. The results show that NTHi-specific IgE antibody is common in serum and secretions in individuals with chronic airways disease and asthma (wheeze).

Subjects that had mild to severe COPD and were treated with the oral vaccine in the active treatment group were found to have a 50% reduction in the usage of bronchodilator therapies. Moreover, eosinophil counts following the administration of a triple course of oral NTHi vaccine therapy were found to be significantly reduced in the active treatment group only. In conclusion, the oral NTHi therapy reduces the usage bronchodilator therapies in acute episodes and also reduces eosinophil counts which are associated with allergic reactions specific to NTHi.

15

EXAMPLE 2

A placebo-controlled double-blind clinical study was performed in which 64 subjects on the basis of having smoked at least 10 cigarettes per day for the past two years were recruited and allocated to oral NTHi therapy or placebo treatment groups in a double-blind study. Subjects were randomised into placebo and active groups and were given three courses of study medication at monthly intervals. Each course consisted of two tablets per day for three days. The active tablets each contained 45mg of formalin-killed NTHi (equivalent to 10^{11} killed bacteria per active tablet). Blood, saliva, gargles, throat swabs, and nasal swabs (for microbiological assessment) were collected at seven fortnightly visits.

25

2.1 Detection of NTHi and measurement of NTHi-specific IgG

Surprisingly, measurements in the placebo-treated and vaccine-treated groups over the winter period detected NTHi in both groups indicating random exposure to the bacterium. Fig. 1 shows the mean level of NTHi in the gargles of the placebo group at each visit.

30

16.

NTHi-specific IgG was measured in serum and saliva by ELISA assay. Briefly, wells of 96-well Nunc Maxisorp plates were coated with H. influenzae 164 sonicate antigen preparation. After incubation overnight at 2-8°C the plates were washed and samples of serum or saliva at various dilutions were added. Following incubation at room temperature for 60 minutes, the plates were washed and horse-radish peroxidase-conjugated anti-human IgG antibody (Chemicon catalogue number AP112P) was added. After incubation for a further 60 minutes at room temperature the plates were washed and TMB substrate (Biomediq catalogue number 50-76-00) was added prior to an additional incubation for 10 minutes at room temperature and the reaction being stopped by addition of 1M phosphoric acid. Absorbance was read on a BioRad microplate reader on dual wavelength mode with a primary filter of 450nm and reference filter of 655nm. A standard curve was used to determine the ELISA units in each sample.

Levels of NTHi-specific IgG in serum and saliva in the placebo group were higher and more variable than the levels in the vaccine-treated group (see Fig. 2 and Fig. 3). The inventors believe this because NTHi reaching the lower airways in the placebo group results in systemic production of IgG and that NTHi was essentially prevented from reaching the lower airways in the vaccine treated group. To test this, plots were prepared of relationship between the number of visits at which NTHi was detected in the gargle and the Log change in serum IgG between visits 1 and 6. Placebo and active subjects were grouped according to whether they had 0-1 visits or 2-4 visits where NTHi was found in the gargle. In the placebo group, positive increases in serum IgG were associated with increased number of NTHi detections. This was not found in the active treatment group. The difference between the placebo and active change in IgG was statistically significant ($p=0.0186$) indicating the serum IgG in the placebo group was indeed generated by NTHi as a result of the bacteria reaching the lower airways. Moreover, the more NTHi present in the placebo washings, the higher the IgG antibody level. This is also believed to apply to the appearance of salivary NTHi-specific IgG in the placebo group.

17.

2.2 Discussion

Serum IgG antibody as a marker for the efficacy of the vaccine was measured. An apparent lack of an IgG response in the vaccine-treated group was found while the placebo treated group of patients showed an increase in serum IgG. Without being
5 limited by theory, it is believed by the inventors that the increase in IgG observed in the placebo group is reflecting an immune response to infecting bacteria reaching the lower airways where uptake of the bacteria by antigen-presenting cells and transport to draining lymph nodes induces an anti-bacterial IgG response. In contrast, the lack of such a response in the vaccine-treated group indicates that the bacteria are being
10 essentially prevented (by a mucosal vaccine-specific immune response) from reaching the lower airways. A comparison of the IgG response in subjects with NTHi detected in the upper airways at 0-1 or 2-4 visits also showed the increase in IgG in the placebo group but not in the active (vaccine) treatment group. This suggests that serum IgG measurement following oral vaccination with NTHi reflects exposure to infection and
15 the degree to which this is prevented by mucosal immunization. The saliva IgG response reflected that seen in the serum.

Overall, this study demonstrates detection of NTHi in the upper respiratory tract of subjects in both the treatment and placebo groups, and that treatment with oral killed NTHi vaccine therapy led to a reduction of NTHi-specific IgG in serum and saliva in
20 the treatment group indicating the vaccine was successful in limiting or preventing access of NTHi to the lower airways (ie., less allergen to initiate asthma).

Thus, only in the placebo group did NTHi access the lower airways as evidenced by stimulation of IgG antibody, and oral 'immunisation' with NTHi vaccine reduced NTHi allergen in the airways
25

EXAMPLE 3 Killed NTHi vaccine orally administered to subjects with mild, moderate or severe airway disease reduce usages of anti-asthma therapy

One hundred and forty human subjects with mild-to-moderate or moderate-to-
30 severe airway disease were recruited into a double blind, placebo-controlled study to assess the effect of an oral killed non-typeable *Haemophilus influenzae* (NTHi) vaccine on number and severity of wheezy reversible airways obstruction, and usage of

18.

concomitant medication as well as the presence of NTHi and other bacteria in the airways.

A reduction in use of anti-asthma-type medication (bronchodilators, steroids etc) and reduced infection by NTHi was found in the treatment group compared to the control group. In particular, a specific reduction of NTHi within the airways of subjects with high IgE antibody
5 levels (serum and secretions) to NTHi, and a reduction in asthma symptoms with a consequential reduction in the need for asthma medication was obtained.

Although the invention has been described with reference to particular examples, the scope of the claims should not be limited by the preferred embodiments set forth in the examples, but should be given the broadest interpretation consistent with the description as a
10 whole.

REFERENCES

1. Abe Y, Murphy TF, Sethi S, Faden HS, Dmochowski J, Harauchi Y, Thanavala YM. Lymphocyte proliferative response to P6 of *Haemophilus influenzae* is associated
5 with relative protection from exacerbations of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2002; **165**: 967-71.
2. Clementsen P, Milman N, Kilian M. et al. Endotoxin from *Haemophilus influenzae* enhances IgE-mediated and non-immunological histamine release. *Allergy* 1990; **45**: 10-17.
- 10 3. Courcol RJ, Damien JM, Ramon P, C Voisin C, Martin GR. Presence of alveolar macrophages as a criterion for determining the suitability of sputum specimens for bacterial culture. *Eur J Clin Microbiol* 1985; **3**: 122-25.
4. Kjaergard LL, Larsen FO, Norn S, Clementsen P, Stahl Skov P, Permin H. Basophil-bound IgE and serum IgE directed against *Haemophilus influenzae* and
15 *Streptococcus pneumoniae* in patients with chronic bronchitis during acute exacerbations. *APMIS* 1996; **104**: 61-67.
5. Kyd JM, Taylor D, Cripps AW. Conservation of immune responses to proteins isolated by preparative polyacrylamide gel electrophoresis from the outer membrane of nontypable *Haemophilus influenzae*. *Infect Immun* 1994; **62**: 5652-58.
- 20 6. Moller LVM, Timens W, van der Bij W et al. *Haemophilus influenzae* in lung explants of patients with end-stage pulmonary disease. *Am J Respir Crit Care Med* 1998; **157**: 950-56.
7. Murphy TF, Bartos LC. Purification and analysis with monoclonal antibodies of P2, the major outer membrane protein of nontypable *Haemophilus influenzae*. *Infect*
25 *Immun* 1988; **56**:1084-89.
8. Murphy TF, Brauer AL, Schiffmacher AT, Sethi S. Persistent colonization by *Haemophilus influenzae* in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2004; **170**: 266-72.
9. Nelson, M.B., M.A. Apicelli., Murphy, T.F., Vankeulen, H., Spotila, L.D.,
30 Rekosh, D. Cloning and sequencing of *Haemophilus influenzae* outer membrane protein P6. *Infect. Immun.* 1988; **56**: 128-134.

20.



10. Norn S, Jensen L, Kjaergard LL, Permin H, Stahl Skov P, Espersen F. Bacteria-induced IgE-mediated histamine release: Examination of patients with chronic bronchitis (CB) during acute exacerbations. *Agents Actions* 41, Special Conference Issue 1994: C22-C23.
- 5 11. Pauwels R, Verschraegen G, Van Der Straeten M. IgE antibodies to bacteria with bronchial asthma. *Allergy* 1980; **157**: 665-9.
12. Rohde G, Gevaert P, Holtappels G et al. Increased IgE-antibodies to *Staphylococcus aureus* enterotoxins in patients with COPD. *Respir Med* 2004; **98**: 858-64.
- 10 13. Seggev JS, Sedmak GV, Kurup VP. Isotype-specific antibody responses to acute *Mycoplasma pneumoniae* infection. *Ann Allergy Asthma Immunol* 1996; **77**: 67-73.
14. Sethi S, Murphy TF. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. *Clin Microbiol Rev* 2001; **14**: 336-363.
- 15 15. Shen J, Brackett R, Fischer T, Holder A, Kellogg F, Michael JG. Specific *Pseudomonas* immunoglobulin E antibodies in sera of patients with cystic fibrosis. *Infect Immun* 1981; **32**: 967-68.
16. Simpson, J.L., Scott, R., Boyle, M.J., Gibson, P.G. Inflammatory subtypes in asthma: Assessment and identification using induced sputum. *Respirology* 2006; **11**, 54-61.
- 20 17. Tee RD, Pepys J. Specific IgE serum antibodies to bacterial antigens in allergic lung disease. *Clin Allergy* 1982; **12**: 439-50.
18. Welliver RC, Wong DT, Middleton E Jr, Sun M, McCarthy N, Ogra PL. Role of parainfluenza virus-specific IgE in pathogenesis of croup and wheezing subsequent to infection. *J Pediatrics* 1982; **101**: 889-96.
- 25

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:


1. Use of a vaccine for prophylaxis or treatment of intrinsic asthma in an individual, the vaccine comprising Non-typable *Haemophilus influenzae* (NTHi) in an amount effective for reducing in the individual one or more of IgE antibodies, asthma symptoms and severity of asthma symptoms, the NTHi being killed or inactivated.
2. The use according to claim 1 wherein the intrinsic asthma is neutrophilic asthma.
3. The use according to claim 1 or 2 wherein the intrinsic asthma is characterised by an elevated neutrophil level in sputum or saliva.
4. The use according to any one of claims 1 to 3 wherein the individual exhibits NTHi specific antibodies.
5. The use according to claim 4 wherein the antibodies are IgE antibodies.
6. The use according to any one of claims 1 to 5 wherein the vaccine is an oral vaccine.
7. The use according to claim 6 wherein the vaccine is an oral killed vaccine.
8. The use according to claim 7 wherein the vaccine comprises one or more whole killed NTHi isolates.
9. The use according to any one of claims 1 to 8, wherein the asthma is characterized by an elevated eosinophil level, and an elevated neutrophil level in sputum or saliva.
10. Use of non-typable *Haemophilus influenza* (NTHi) for the manufacture of a medicament for the prophylaxis or treatment of intrinsic asthma, the NTHi being killed or inactivated.
11. The use according to claim 10 wherein said medicament is an oral killed vaccine.
12. The use according to claim 11 wherein said medicament comprises at least one antigen selected from killed or inactivated Non-typable *Haemophilus influenzae* (NTHi) isolates, NTHi fractions and antigenic outer membrane components, wherein the NTHi fractions comprise at least one membrane protein or antigenic fragments thereof.
13. The use according to claim 12 wherein said medicament comprises one or more whole killed NTHi isolates.
14. The use according to any one of claims 10 to 13, wherein the asthma is characterized by an elevated eosinophil level, and an elevated neutrophil level in sputum or saliva.
15. Use of at least one antigen for prophylaxis or treatment of intrinsic asthma in an individual, wherein the at least one antigen is a killed or inactivated Non-typable *Haemophilus influenzae*

- (NTHi) isolate, NTHi fraction or antigenic outer membrane component, wherein the NTHi fraction comprises at least one membrane protein or antigenic fragment thereof.
16. The use according to claim 15 wherein the at least one antigen comprises one or more whole killed NTHi isolates.
 17. The use according to claim 15 or 16, wherein the asthma is characterized by an elevated eosinophil level, and an elevated neutrophil level in sputum or saliva.
 18. Use of an antigen which generates a response against Non-typable *Haemophilus influenzae* (NTHi) in the manufacture of a medicament for the prophylaxis or treatment of asthma in an individual exhibiting NTHi specific IgE antibodies indicative of exposure to NTHi, wherein the antigen is one or more killed or inactivated NTHi isolates, NTHi fractions or antigenic outer membrane components, and wherein the NTHi fractions comprise at least one membrane protein or antigenic fragments thereof, and said antigen is used in a vaccine such that administration of the vaccine to the individual leads to a reduction in the individual of one or more of IgE antibodies, symptoms of the asthma and severity of the asthma.
 19. The use according to claim 18, wherein the IgE antibodies are measured in sputum or saliva.
 20. The use according to claim 18 or 19, wherein the vaccine is an oral vaccine.
 21. The use according to claim 20, wherein the oral vaccine is a killed vaccine.
 22. The use according to claim 21, wherein the oral killed vaccine comprises one or more whole killed NTHi isolates.
 23. The use according to any one of claims 18 to 22, wherein the asthma is characterized by an elevated eosinophil level, and an elevated neutrophil level in sputum or saliva.

1/2

FIGURE 1**FIGURE 2**

2/2

FIGURE 3

Saliva: NTHi-specific IgG

